Antiarrhythmic efficiency of eplerenon in complex therapy of patients with arterial hypertension and frequent recurrences of atrial fibrillation

Article Sidebar

PDF (Ukrainian)
Published: Sep 11, 2018
DOI: https://doi.org/10.31928/1608-635X-2018.4.8190
How to Cite
“Antiarrhythmic Efficiency of Eplerenon in Complex Therapy of Patients With Arterial Hypertension and Frequent Recurrences of Atrial Fibrillation”. Ukrainian Journal of Cardiology, vol. 25, no. 4, Sept. 2018, pp. 81-90, https://doi.org/10.31928/1608-635X-2018.4.8190.
Issue
Vol. 25 No. 4 (2018): Ukrainian Journal of Cardiology
Section
Cardiac arrhythmias

Main Article Content

V. P. Ivanov
National Pirogov Memorial Medical University, Vinnytsia
T. D. Danilevych

Abstract

The aim – to determine antiarrhythmic efficiency of eplerenone in the complex therapy of patients with arterial hypertension (AH) and frequent recurrences of atrial fibrillation (AF).
Material and methods. 146 patients with AH II stage and frequent recurrences of AF were examined. The age of the patients was from 37 till 86 years. Among them 68 (46.6 %) were males. Permanent antiarrhythmic therapy was prescribed in all patients. The antiarrhythmic efficiency was evaluated by patient-reported frequency of AF attacks and their course. Fixed combinations of perindopril with indapamide and losartan with hydrochlorothiazide were used as a starting antihypertensive therapy. Eplerenone 25 mg daily was added in a number of the patients. All patients were examined by determining serum aldosterone levels and daily ECG monitoring.
Results. Usage of eplerenone during 6 months decreased frequency of recurrences of AF and increased the duration of the period between recurrences (4.8 vs. 3.2 times, P=0.04). Antiarrhythmic effect of eplerenone was accompanied by significant increase of cases with complete elimination of supraventricular premature contractions (SPC) (P<0.001) and AF episodes (p=0.05), significant decrease of daily SPC frequency (P=0.007) and supraventricular paroxysmal tachycardias / atrial flutter episodes (P<0.04), decrease of QT interval dispersion (P<0.04). The probability of complete antiarrhythmic efficacy with additional use of eplerenone was significantly more in case of the adrenal AF (P<0.03). Factors increasing the probability of complete antiarrhythmic efficacy of eplerenone were: daily heart rate
> 78 per minute, the ratio of left atrium /right atrium < 1.45, using of losartan in a dose of 100 mg/day, the dynamics of systolic blood pressure (BP) at the 4th week of treatment according to data of office measurement of BP > 32 mm Hg, and plasma level of aldosterone > 150 pg/ml.
Conclusions. Eplerenone provided additional antiarrhythmic effect in patients with AH and paroxysmal AF. Positive antiarrhythmic effect of eplerenone accompanied by a significant increase in cases with a complete elimination of SPC and AF episodes, significant decrease in the frequency of SPC for the day and SVPT/AF episodes, decrease in the dispersion of QT interval. The probability of complete antiarrhythmic efficacy with additional use of eplerenone significantly increases in the case of adrenal variant and decreases in the case of vagal varian of AF. As factors that increase the probability of complete antiarrhythmic efficacy of eplerenone are: daily HR > 78, the ratio LA/RA < 1.45, using of losartan in a dose of 100 mg/day, the dynamic of systolic BP at the 4th week of treatment according to data of office measurement of BP > 32 mm hg and plasma level of aldosterone > 150 pg/ml.

Article Details

Keywords:

Arterial hypertension, atrial fibrillation, eplerenone, aldosterone

References

Bunin JUA, Fedjakina LF. Kombinirovannaja profilakticheskaja antiaritmicheskaja farmakoterapija fibrilljacii i trepetanija predserdij. Rossijskij kardiologicheskij zhurnal [Russian Cardiology Journal] 2006;6:35–45 (in Russ).

Voronkov LG. Aldosteron i ego blokada pri serdechno sosudistoj patologii. Sertseva nedostatnist. [ Heart failure] 2013;1:53–61 (in Russ).

Zharinov OI, Talaieva TV, Lishchyshyna OM, Bozhko LI, Hetman TV, Zalevskyi VP, Karpenko IuI, Klymenko LV, Matiukha LF, Netiazhenko VZ, Romanova OM, Rudenko KV, Sychov OS, Stychynskyi OS, Khimion LV, Yabluchanskyi MI, Yahenskyi AV. Adaptovana klinichna nastanova, zasnovana na dokazakh. Fibryliatsiia peredserd. Rekomendatsii Robochoi hrupy z porushen rytmu sertsia Asotsiatsii kardiolohiv Ukrainy [Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the Ukrainian Society of heart rhythm disorders] 2016;136. (in Ukr).

Ivanov VP, Danilevych TD. Rol aldosteronu v rozvytku fibryliatsii peredserd, antyaldosteronova kontseptsiia v upstream-terapii. Kardiologija ot nauki k praktike [Cardiology from science to practice] 2016;1:89–101 (in Ukr).

Pavlov EG, Chapurnyh AV, Solov'ev OV. Primenenie jetacizina v kombinirovannoj terapiirecidivirujushhej fibrilljacii. Kardiologija i serdechno-sosudistaja hirurgija [Cardiology and cardiovascular surgery] 2010;1(3):64–70 (in Russ).

Rebrova OIu. Statisticheski analiz medicinskih dannyh. Primenenie paketa prikladnyh programm STATISTICA [Statistical analysis of medical data. Application of the STATISTICA software package]. MedyaSfera 2006;312 (in Russ).

Sychov OS, Lutai MI, Romanova OM. Ambulatorne EKH-monitoruvannia. Rekomendatsii Asotsiatsii kardiolohiv Ukrainy [Guidelines of the Association of Cardiologists of Ukraine], Kyiv 2010;44 (in Ukr.).

Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Fibryliatsiia peredserd. Nakaz MOZ № 597 vid 15.06.2016 (in Ukr).

Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Arterialna Hipertenziia № 384 vid 24.05.2012 (in Ukr).

Fomina IG, Tarzimanova AI, Vetluzhskij AV, Abramova AA. Propafenon pri vosstanovlenii sinusovogo ritma u bol'nyh s persistirujushhej formoj fibrilljacii predserdij. «PROMETEJ» – otkrytoe, mul'ticentrovoe, pilotnoe issledovanie v Rossijskoj Federacii. Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular therapy and prevention] 2005;4(5):62–65 (in Russ).

Furman NV, SHmatova SS, Dovgalevskij PJA. Dlitel'nost' i dispersija intervalov QT i QTc pri vypolnenii stress-testa bol'nymi ishemicheskoj bolezn'ju serdca s zheludochkovymi narushenijami ritma. Kardiovaskuljarnaja terapija i profilaktika – Cardiovascular therapy and prevention 2006;5(8):48–51 (in Russ).

Celujko V.I., Radchenko O.V. Holterovskoe monitorirovanie v diagnostike narushenij ritma i provodimosti serdca. Liky Ukrainy [Medicines of Ukraine] 2016;5-6:21–35 (in Russ).

Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: RH Falk, PJ Podrid, eds. Atrial fibrillation. Mechanisms and management. New York: Raven Press, 1992:109–25.

Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T, Schirdewan A, Reuter H, Mueller-Ehmsen J, Zobel C. Aldosterone induces electrical remodeling independent of hypertension. International Journal of Cardiology 2013;164(2):170–178.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hindricks JHG, Manolis AS, Oldgren J, Popescu BA, Schotten U, Putte BV, Varda P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J 2016;37:2893–2962.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1):1–39.

Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.

Moe GW, Laurent G, Doumanovskaia L, Konig A, Hu X, Dorian P. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure. Journal of Cardiac Failure 2008;14(9):768–776.

Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. Journal of Cardiovascular Electrophysiology 2006;17:534–541.